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Background: Most compelling epidemiological, experimental and clinical evidence for eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) effect on the reduction of cardiovascular mortality (in particular its ability to reduce the risk of sudden death) focuses on the anti-arrhythmic 
mechanism of action.We sought to study the antiarrhythmic effect by a randomized crossover placebo controlled study in post myocardial infarction 
(MI) ICD patients.
Methods: 105 post MI patients with ICD received 3.6 gram of EPA and DHA and placebo for 6 months each at a random order with a 4-month 
washout period between treatments. 87 patients completed the 16 months study protocol. We looked at arrhythmic episodes stored by the ICDs.
Results: No differences were found in mean number of NSVT episodes or number of patients experiencing NSVT episodes between placebo and 
fish-oil treatment (3.24 ± 15.1 vs. 1.09 ± 2.7, p= 0.170 respectively ). 23 patients in each one of the fish-oil and the placebo period experienced 
NSVT episode. No difference was found between mean number of VT episodes terminated with ATP or number of patients experienced VT episodes 
terminated with ATP between placebo and fish-oil treatment (2.8 ± 13.7 vs. 0.5 ± 2.1 p=0.077 respectively and 16 vs. 13 patients p=0.627). 
No difference where found comparing mean number of VT/VF episodes terminated with shock or number of patients experienced VT/VF episodes 
terminated with shock between placebo and fish-oil treatment (0.11 ± 0.6 vs. 0.10 ± 0.4, p=0.874 respectively and 5 vs. 7 patients p=0.727).
Conclusions: This study failed to show neither protective effect nor proarrhythmic effect of fish-oil in post MI patients with ICD.. Our data do not 
support fish oil supplementation to reduce arrhythmic events in patients with ICD.
